NCT05806931 2026-03-18
SCOTI
Rutgers, The State University of New Jersey
Phase 2 Recruiting
Clinical Trials
21 trialsNCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04511039 2026-03-02
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06856837 2025-12-12
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07085169 2025-07-25
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Phase 2 Recruiting
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05965531 2025-04-29
TASLARC
Sun Yat-sen University
Phase 2 Recruiting
NCT04920032 2025-04-08
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT06711471 2024-12-02
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT06485713 2024-07-03
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Recruiting
NCT06379399 2024-04-23
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06202001 2024-04-02
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04660760 2024-04-01
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT05007132 2024-02-15
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Charite University, Berlin, Germany
Phase 2 Recruiting
NCT06242067 2024-02-05
BEV-TASIRI
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05970705 2023-08-01
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University
Phase 2 Recruiting